Kymera Therapeutics (KYMR) Q2 2026 earnings call: accelerated KT-621 AD timeline, KT-579 lupus plans, partner milestones, and runway to 2029—read now.
$KYMR
Price history, market instrument context, member research, and related headlines in one place.
KYMR key statistics
NasdaqGMUSD
52-week range
$55.2671%$130.05
Latest session $104.63–$110.68Kymera Therapeutics, Inc. (KYMR) is a stock instrument quoted on NasdaqGM in USD. The most recently published price is $108.14, up $1.31 (1.23%) from the previous close of $106.83. It has traded between $104.63 and $110.68 in the latest session. Over the past year it has ranged from $55.26 to $130.05, leaving it in the upper half of its 52-week range (71%). Reported volume for the session was 821K. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Kymera Therapeutics Q2 2026 Earnings Preview — See source for full details.
Kymera Therapeutics names Terence Rooney as chief medical officer — See source for full details.
Loading $KYMR research…